Skip to content

Trial Summary

A Phase 1, Single-Centre, Non-Randomised, Open-Labelled, 2-Arm, Single Dose study of Chimeric Anti- La/SSB Antibody (APOMAB) Conjugated with 89Zirconium-Label (89Zr-APOMAB) as a Theranostic Imaging Agent Using ImmunoPET/CT in Patients with Advanced Lung or Ovarian Cancer

Acronym:

APOMAB

ACTRN/NCT /ethics:

 

Scientific title:

A Phase 1, Single-Centre, Non-Randomised, Open-Labelled, 2-Arm, Single Dose study of Chimeric Anti- La/SSB Antibody (APOMAB) Conjugated with 89Zirconium-Label (89Zr-APOMAB) as a Theranostic Imaging Agent Using ImmunoPET/CT in Patients with Advanced Lung or Ovarian Cancer

Trial & Patient Characteristics

Cancer TypeGynaecological, Lung & Mesothelioma
Trial TypeTreatment
PhasePhase I
Age Range18+ years
SexBoth
Tumour StreamLung or Ovarian Cancer
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-06-01
Anticipated End Date2021-12-31

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting